What's behind
Glutamate carboxypeptidase II
Immunohistochemistry
Neoplasm staging
Positron emission tomography
Prostatic neoplasms
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
24
04
2021
accepted:
18
07
2021
pubmed:
14
8
2021
medline:
21
10
2021
entrez:
13
8
2021
Statut:
ppublish
Résumé
Prostate-specific membrane antigen (PSMA-) PET has become a promising tool in staging and restaging of prostate carcinoma (PCa). However, specific primary tumour features might impact accuracy of PSMA-PET for PCa detection. We investigated histopathological parameters and immunohistochemical PSMA expression patterns on radical prostatectomy (RPE) specimens and correlated them to the corresponding RPE specimens of 62 patients with preoperative All tumours showed medium to strong membranous (2-3 +) and weak to strong cytoplasmic (1-3 +) PSMA expression. Heterogeneously expressed PSMA was found in 38 cases (61%). Twenty-five cases (40%) showed at least 5% and up to 80% PSMA We describe PSMA
Identifiants
pubmed: 34386839
doi: 10.1007/s00259-021-05501-1
pii: 10.1007/s00259-021-05501-1
pmc: PMC8484204
doi:
Substances chimiques
Gallium Isotopes
0
Gallium Radioisotopes
0
Oligopeptides
0
gallium 68 PSMA-11
0
Edetic Acid
9G34HU7RV0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4042-4053Informations de copyright
© 2021. The Author(s).
Références
O’Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT, et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta. 1998;1443(1–2):113–27.
doi: 10.1016/S0167-4781(98)00200-0
Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology. 2007;50(4):472–83.
doi: 10.1111/j.1365-2559.2007.02635.x
Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38(5):696–701.
doi: 10.1016/j.humpath.2006.11.012
Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9(17):6357–62.
pubmed: 14695135
Hupe MC, Philippi C, Roth D, Kumpers C, Ribbat-Idel J, Becker F, et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol. 2018;8:623.
doi: 10.3389/fonc.2018.00623
Kranzbuhler B, Muller J, Becker AS, Garcia Schuler HI, Muehlematter U, Fankhauser CD, et al. Detection rate and localization of prostate cancer recurrence using (68)Ga-PSMA-11 PET/MRI in patients with low PSA values </= 0.5 ng/mL. J Nucl Med. 2020;61(2):194–201.
doi: 10.2967/jnumed.118.225276
Burger IA, Muller J, Donati OF, Ferraro DA, Messerli M, Kranzbuhler B, et al. (68)Ga-PSMA-11 PET/MR detects local recurrence occult on mpmri in prostate cancer patients after HIFU. J Nucl Med. 2019;60(8):1118–23.
doi: 10.2967/jnumed.118.221564
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–16.
doi: 10.1016/S0140-6736(20)30314-7
Muehlematter UJ, Burger IA, Becker AS, Schawkat K, Hotker AM, Reiner CS, et al. Diagnostic accuracy of multiparametric MRI versus (68)Ga-PSMA-11 PET/MRI for extracapsular extension and seminal vesicle invasion in patients with prostate cancer. Radiology. 2019;293(2):350–8.
doi: 10.1148/radiol.2019190687
Woo S, Ghafoor S, Becker AS, Han S, Wibmer AG, Hricak H, et al. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis. Eur J Hybrid Imaging. 2020;4(1):16.
doi: 10.1186/s41824-020-00085-9
Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous (68)Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016;70(5):829–36.
doi: 10.1016/j.eururo.2015.12.053
Park SY, Zacharias C, Harrison C, Fan RE, Kunder C, Hatami N, et al. Gallium 68 PSMA-11 PET/MR imaging in patients with intermediate- or high-risk prostate cancer. Radiology. 2018;288(2):495–505.
doi: 10.1148/radiol.2018172232
Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195(5):1436–43.
doi: 10.1016/j.juro.2015.12.025
Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, et al. Risk of metastatic disease on (68) gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int. 2019;124(3):401–7.
doi: 10.1111/bju.14828
Muehlematter UJ, Rupp NJ, Mueller J, Eberli D, Burger IA. 68Ga-PSMA PET/MR-positive, histopathology-proven prostate cancer in a patient with negative multiparametric prostate MRI. Clin Nucl Med. 2018;43(8):e282–4.
doi: 10.1097/RLU.0000000000002143
Lopci E, Saita A, Lazzeri M, Lughezzani G, Colombo P, Buffi NM, et al. (68)Ga-PSMA positron emission tomography/computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging: a prospective observational study. J Urol. 2018;200(1):95–103.
doi: 10.1016/j.juro.2018.01.079
Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15(2):167–72.
doi: 10.1007/s12253-008-9104-2
Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76(4):469–78.
doi: 10.1016/j.eururo.2019.06.030
Pizzuto DA, Muller J, Muhlematter U, Rupp NJ, Topfer A, Mortezavi A, et al. The central zone has increased (68)Ga-PSMA-11 uptake: “Mickey Mouse ears” can be hot on (68)Ga-PSMA-11 PET. Eur J Nucl Med Mol Imaging. 2018;45(8):1335–43.
doi: 10.1007/s00259-018-3979-2
Ferraro DA, Rupp NJ, Donati OF, Messerli M, Eberli D, Burger IA. 68Ga-PSMA-11 PET/MR can be false positive in normal prostatic tissue. Clin Nucl Med. 2019;44(4):e291–3.
doi: 10.1097/RLU.0000000000002473
Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen JC, Huang K, et al. Immunohistochemical validation of PSMA expression measured by (68)Ga-PSMA PET/CT in primary prostate cancer. J Nucl Med. 2018;59(2):238–43.
doi: 10.2967/jnumed.117.195172
Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105.
doi: 10.1016/j.eururo.2016.02.029
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–52.
doi: 10.1097/PAS.0000000000000530
Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48(6):932–45.
doi: 10.2967/jnumed.106.035774
Rupp NJ, Umbricht CA, Pizzuto DA, Lenggenhager D, Topfer A, Muller J, et al. First clinicopathologic evidence of a non-PSMA-related uptake mechanism for (68)Ga-PSMA-11 in salivary glands. J Nucl Med. 2019;60(9):1270–6.
doi: 10.2967/jnumed.118.222307
Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. Ga-68-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014–24.
doi: 10.1007/s00259-017-3670-z
Demirci E, Kabasakal L, Sahin OE, Akgun E, Gultekin MH, Doganca T, et al. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? Nucl Med Commun. 2019;40(1):86–91.
doi: 10.1097/MNM.0000000000000942
van der Kwast TH, van Leenders GJ, Berney DM, Delahunt B, Evans AJ, Iczkowski KA, et al. ISUP consensus definition of cribriform pattern prostate cancer. Am J Surg Pathol. 2021;45(8):1118–1126.
Ferraro DA, Ruschoff JH, Muehlematter UJ, Kranzbuhler B, Muller J, Messerli M, et al. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with (68)Ga-PSMA-11-PET. Theranostics. 2020;10(14):6082–94.
doi: 10.7150/thno.44584